What is Surmodics?
Surmodics stands as a global leader in surface modification technologies, primarily serving the intravascular medical device industry. The company also holds a prominent position as a provider of essential chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Beyond its core component offerings, Surmodics actively designs and produces highly differentiated medical devices aimed at addressing critical unmet clinical needs within intravascular medicine.
How much funding has Surmodics raised?
Surmodics has raised a total of $140M across 2 funding rounds:
Stock Offering
$15M
Debt
$125M
Stock Issuance/Offering (1998): $15M, investors not publicly disclosed
Debt (2022): $125M led by MidCap Financial
Key Investors in Surmodics
MidCap Financial
MidCap Financial is a lender that tailors flexible financing solutions, focusing on providing quick and efficient capital to support business objectives.
What's next for Surmodics?
The recent major strategic investment suggests Surmodics is poised for accelerated expansion, likely focusing on enhancing its technological capabilities, broadening its product portfolio, and potentially increasing market penetration. This capital infusion is expected to fuel further innovation in surface modification and IVD components, reinforcing its competitive edge and supporting the development of advanced medical devices.
See full Surmodics company page